198 related articles for article (PubMed ID: 32584842)
1. Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.
Angrimani DSR; Francischini MCP; Brito MM; Vannucchi CI
PLoS One; 2020; 15(6):e0234714. PubMed ID: 32584842
[TBL] [Abstract][Full Text] [Related]
2. Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically.
Lima CB; Angrimani DSR; Flores RB; Vannucchi CI
Domest Anim Endocrinol; 2021 Apr; 75():106601. PubMed ID: 33333452
[TBL] [Abstract][Full Text] [Related]
3. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
[TBL] [Abstract][Full Text] [Related]
4. Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs.
Angrimani DSR; Brito MM; Rui BR; Nichi M; Vannucchi CI
Sci Rep; 2020 Sep; 10(1):14834. PubMed ID: 32908208
[TBL] [Abstract][Full Text] [Related]
5. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M
Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076
[TBL] [Abstract][Full Text] [Related]
6. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
7. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs.
Iguer-Ouada M; Verstegen JP
J Reprod Fertil Suppl; 1997; 51():139-49. PubMed ID: 9404280
[TBL] [Abstract][Full Text] [Related]
8. Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy.
Sirinarumitr K; Johnston SD; Kustritz MV; Johnston GR; Sarkar DK; Memon MA
J Am Vet Med Assoc; 2001 Apr; 218(8):1275-80. PubMed ID: 11330612
[TBL] [Abstract][Full Text] [Related]
9. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients.
Pareek G; Shevchuk M; Armenakas NA; Vasovic L; Hochberg DA; Basillote JB; Fracchia JA
J Urol; 2003 Jan; 169(1):20-3. PubMed ID: 12478093
[TBL] [Abstract][Full Text] [Related]
10. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
11. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
12. [Benign prostatic hyperplasia: treatment options in the dog].
Renggli M; Padrutt I; Michel E; Reichler I
Schweiz Arch Tierheilkd; 2010 Jun; 152(6):279-84. PubMed ID: 20533201
[TBL] [Abstract][Full Text] [Related]
13. Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy.
Sirinarumitr K; Sirinarumitr T; Johnston SD; Sarkar DK; Kustritz MV
Am J Vet Res; 2002 Apr; 63(4):495-8. PubMed ID: 11939309
[TBL] [Abstract][Full Text] [Related]
14. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.
Lekas AG; Lazaris AC; Chrisofos M; Papatsoris AG; Lappas D; Patsouris E; Deliveliotis C
Urology; 2006 Aug; 68(2):436-41. PubMed ID: 16904480
[TBL] [Abstract][Full Text] [Related]
15. Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs.
Dearakhshandeh N; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Abbaszadeh Hasiri M; Golchin-Rad K
Theriogenology; 2020 Jan; 142():236-245. PubMed ID: 31711694
[TBL] [Abstract][Full Text] [Related]
16. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
17. Effects of finasteride on vascular endothelial growth factor.
Häggström S; Tørring N; Møller K; Jensen E; Lund L; Nielsen JE; Bergh A; Damber JE
Scand J Urol Nephrol; 2002; 36(3):182-7. PubMed ID: 12201932
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A
Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095
[TBL] [Abstract][Full Text] [Related]
19. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
20. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
